it is a human immunoglobulin g1 kappa igg1 monoclonal antibody that blocks the interaction of programmed cell death ligand 1 pd l1 with the pd 1 cd279 durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy durvalumab is known as a checkpoint inhibitor drug the list price for the drug from astrazeneca is 180 000 for a year a phase 1b clinical trial of durvalumab and tremelimumab showed some activity in non small cell lung cancer nsclc phase 1 data in advanced metastatic urothelial bladder study 1108 has led to fda breakthrough therapy designation early results of a phase i trial combining durvalumab and gefitinib in lung cancer patients showed promise a phase 1 clinical trial is currently underway using durvalumab with a tlr 7 8 agonist medi 9197 for solid tumors a phase 1b 2a trial is underway combining durvalumab with an hpv dna vaccine medi 0457 in patients with hpv associated recurrent metastatic head and neck cancer in july 2017 astrazeneca announced that a phase